← The record

Amino Acid Formula With Vitamins And Minerals Without Methionine, Threonine And Valine And Low In Isoleucine

Recommended MetabolicRestrictedNot applicable line 💬 consumer voice

Dietary management of patients with a proven diagnosis of methylmalonic acidaemia (MMA) or propionic acidaemia (PA).

2
Submissions
2015–24
On the record
ICER range
Cost-min
Cost basis

Decision on record

1 decision
  • Meeting Nov 2024 Recommended Methylmalonic acidaemia; propionic acidaemia

Access path

2 submissions · public record
  1. Nov 2015
    Recommended · restricted

    vs MMA/PA Gel® and XMTVI Maxamaid®

  2. Nov 2024
    Recommended · restricted

    Comparator changed: MMA/PA Gel® and XMTVI Maxamaid® → MMA/PA Anamix Junior and MMA/PA…

  3. PBS listing · Restricted
RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
7.1 The PBAC recommended a General Schedule Restricted Benefit listing of amino acid formula with vitamins and minerals without methionine, threonine and valine and low in isoleucine, sachets containing oral powder 12.5 g, 30 (MMA/PA explore5™) for the dietary management of patients with a proven diagnosis of methylmalonic acidaemia (MMA) or propionic acidaemia (PA), under the same circumstances as the current listings for MMA/PA Anamix Junior and MMA/PA …PSD · Nov 2024
7.2 The PBAC considered that MMA/PA explore5 should be cost-minimised to the lowest cost comparator accepted by the NPWP (i.e., MMA/PA Anamix Junior and MMA/PA Anamix Infant) at an equivalent price per gram of protein equivalent.PSD · Nov 2024
Economic analysis
5.9 The submission presented a cost-minimisation analysis of MMA/PA explore5 compared to MMA/PA Anamix Junior, based on the same cost per gram of PE. While MMA/PA Anamix Infant is also a main comparator, it was excluded from the economic analysis as the submission claimed MMA/PA Anamix Infant is an infant protein substitute whereas MMA/PA explore5 and MMA/PA Anamix Junior are ‘second-stage’ protein substitutes.PSD · Nov 2024
5.10 The protein equivalent content and proposed price of MMA/PA explore5, in comparison to MMA/PA Anamix Junior, are outlined in Table 2.PSD · Nov 2024
Clinical claim
5.8 The submission claimed that MMA/PA explore5 is therapeutically comparable to MMA/PA Anamix Junior and MMA/PA Anamix Infant.PSD · Nov 2024

Cost-effectiveness

Cost-minimisation analysis; no ICER calculated by design.

The PBAC considered that MMA/PA explore5 should be cost-minimised to the lowest cost comparator accepted by the NPWP (i.e., MMA/PA Anamix Junior and MMA/PA Anamix Infant) at an equivalent price per gram of protein equivalent. PBAC · 2024
Price cut / RSA neededCost-effectiveness accepted

Decision context

PopulationInfants and children aged six months to five years with a proven diagnosis of methylmalonic acidaemia (MMA) or propionic acidaemia (PA).

Submission history

2 entries
DecidedOutcomeComparatorICEREvidence
Nov 2024 Recommended · restricted MMA/PA Anamix Junior and MMA/PA Anamix Infant Cost-minimisation · Cost-minimisation
Nov 2015 Recommended · restricted MMA/PA Gel® and XMTVI Maxamaid® Cost-minimisation · Cost-minimisation

Consumer voice

Nov 2015

No consumer comments were received for this item.

The PBAC noted that no consumer comments were received for this item. Consumer comments · PSD

Similar precedents

By decision profile